Goldman Sachs Upgrades TG Therapeutics to Neutral, Lowers Price Target to $12
Portfolio Pulse from richadhand@benzinga.com
Goldman Sachs analyst Corinne Jenkins has upgraded TG Therapeutics from Sell to Neutral and lowered the price target from $16 to $12.
August 04, 2023 | 11:11 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
TG Therapeutics has been upgraded to Neutral from Sell by Goldman Sachs, but the price target has been lowered to $12.
The upgrade from Sell to Neutral indicates a more positive outlook for TG Therapeutics, which could potentially stabilize the stock price. However, the lowering of the price target from $16 to $12 suggests that Goldman Sachs sees less upside potential in the stock, which could limit its short-term growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100